Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily and form heterodimers with retinoid X receptor. Three PPAR isoforms have been isolated and termed α, β (or δ) and γ. Although PPARγ is expressed predominantly in adipose tissue and associated with adipocyte differentiation and glucose homeostasis, PPARγ is also present in a variety of cell types. Synthetic antidiabetic thiazolidinediones (TZDs) are well known as ligands and activators for PPARγ. After it was reported that activation of PPARγ suppressed production of pro-inflammatory cytokines in activated macrophages, medical interest in PPARγ has grown and there has been a huge research effort. PPARγ is currently known to be implicated in various human chronic diseases such as diabetes mellitus, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, and Alzheimer's disease. Many studies suggest that TZDs not only ameliorate insulin sensitivity, but also have pleiotropic effects on many tissues and cell types. Although activation of PPARγ seems to have beneficial effects on cardiovascular diseases, the mechanisms by which PPARγ ligands prevent their development are not fully understood. Recent data about the actions and its mechanisms of PPARγ-dependent pathway in cardiovascular diseases are discussed here. (Circ J 2009; 73: 214 -220) 
eroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily that heterodimerize with the retinoid X receptor (RXR) and bind to specific response elements termed PPAR responsive elements (PPREs) in target gene promoters. The PPREs are direct repeats of the hexameric consensus sequence AGGTCA, separated by 1 nucleotide. These nuclear receptors are ligand-dependent transcription factors, and activation of target gene transcription depends on the binding of the ligand to the receptor. PPARs have 3 isoforms, α, β (or δ) and γ. PPARα regulates genes involved in fatty acid oxidation, whereas PPARγ promotes adipocyte differentiation and glucose homeostasis. The main function of PPARβ/ δ has yet to be ascertained, but involvement in the regulation of fatty acid oxidation seems likely. PPARα is present mainly in the liver, kidney, and muscle, whereas PPARγ is expressed predominantly in adipose tissue. PPARβ/ δ is almost ubiquitously expressed. It was recently demonstrated that PPARγ is also expressed in a variety of cell types. After it was reported that activation of PPARγ suppresses production of inflammatory cytokines in activated macrophages, medical interest in PPARγ has grown, along with a huge research effort.
PPARγ
Peroxisome is a subcellular organelle that plays a crucial role in cellular metabolism. Peroxisome enzymes are implicated in a broad range of catabolic and anabolic enzymatic pathways, such as fatty acid oxidation, biosynthesis of both glycerolipids and cholesterol, and metabolism of reactive oxygen species. Peroxisome proliferation induced in rodents is associated with cellular responses to a range of chemical compounds. In 1990, Issemann and Green reported that peroxisome proliferators activate a member of the steroid hormone receptor superfamily in mouse liver. 1 This nuclear receptor was named PPAR. Soon after, 3 major types of PPAR ( α, β/ δ, and γ) were recognized. PPARγ is associated with adipocyte differentiation and glucose homeostasis. PPARγ is expressed in a variety of cell types, including adipocytes, macrophages, vascular smooth muscle cells (VSMCs), endothelial cells (ECs), and cardiomyocytes. [2] [3] [4] [5] [6] [7] Several lines of evidence have demonstrated the functional significance of PPARγ in atherosclerotic lesions. 8, 9 Activity of PPARγ is depressed by phosphorylation of a serine residue (Ser 112 ) in the N-terminal domain, mediated by a member of the mitogen-activated protein (MAP) kinase family, extracellular signal-regulated protein kinase (ERK). In addition, another member of MAP kinase family, c-Jun N-terminal kinase (JNK) also phosphorylates PPARγ at Ser 82 and reduces the transcriptional activity of PPARγ. The association of PPARγ polymorphism with metabolic syndrome has also been examined. 10, 11 In the presence of ligand, PPARγ binds to coactivator complexes, resulting in the activation of target genes. In the absence of ligand, PPARγ binds to the promoters of several target genes and associates with a corepressor complex, leading to active repression of target genes. This process is referred to as active repression (Fig 1) . The corepressor complex constitutes corepressor proteins, such as nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid hormone receptors, histone deacetylases (HDACs) and transducin β-like protein 1 (TBL1). HDACs are essential in maintaining repressed chromatin structure and TBL1 exchanges a corepressor complex for a coactivator complex in the presence of ligand. 12 Many nuclear receptors are proposed to sequester inflammatory transcription factors, such as nuclear factor-κB (NF-κB) and AP-1, by inhibiting their DNA-binding activities, resulting in inhibition of inflammatory target genes. In the presence of ligand, PPARγ also interacts with inflammatory transcription factors and inhibits their DNA-binding activities. PPARγ blocks clearance of the corepressor complex in a ligand-dependent manner, and PPARγ stabilizes the corepressor complex bound to the promoter of inflammatory genes. 13 It was demonstrated that PPARγ associates with the protein inhibitor of activated STAT1 (PIAS1), which is a small ubiquitin-like modifier (SUMO)-E3 ligase, in a liganddependent manner. PIAS1-induced SUMOylation of the ligand-binding domain of PPARγ enables the receptor to maintain NCoR on the promoter of inflammatory genes. 14 These are the suggested mechanisms of PPARγ transrepression.
PPARγ Ligands
Natural and synthetic ligands bind to PPARγ, resulting in conformational change and activation of PPARγ. The PGD2 metabolite, 15d-PGJ2, was the first endogenous ligand for PPARγ to be discovered. Although 15d-PGJ2 is the most potent natural ligand of PPARγ, the extent to which its effects are mediated through PPARγ in vivo remains to be determined. Two components of oxidized low density lipoprotein (ox-LDL), the 9-hydroxy and 13-hydroxy octadecadienoic acids (HODE), are also potent endogenous activators of PPARγ. 15, 16 Activation of 12/15-lipoxygenase induced by interleukin (IL)-4 also produced endogenous ligands for PPARγ; 17 however, whether these natural ligands act as physiological PPARγ ligands in vivo remains unknown. The antidiabetic thiazolidinediones (TZDs), such as troglitazone, pioglitazone, ciglitazone and rosiglitazone, which are used to control glucose concentration in patients with diabetes mellitus (DM), are pharmacological ligands of PPARγ. They bind PPARγ with various affinities and it is conceivable that their insulin-sensitizing and hypoglycemic effects are exerted by activating PPARγ. However, the molecular mechanisms by which TZDs affect insulin resistance and glucose homeostasis are not fully understood. They seem to mediate their effects primarily through adipose tissue, because TZDs alter the expression level of genes that are involved in lipid uptake, lipid metabolism and insulin action in adipocytes. TZDs enhance adipocyte insulin signaling and reduce the release of free fatty acids. TZDs also decrease the inflammation of adipose tissue that is induced by obesity and contributes to increased insulin resistance. There is a possibility that TZDs improve insulin sensitivity in skeletal muscle and liver, the main insulin-sensitive organs, through these multiple adipocentric actions. PPARγ has been demonstrated to have an antiinflammatory effect, leading to initiation of treatment trials for patients with inflammatory diseases. RXR, which interacts with the PPARs, is activated by 9-cis retinoic acid. When combined as a PPAR:RXR heterodimer, the PPAR ligands and 9-cis retinoic acid act synergistically on PPAR responses.
PPARγ and Atherosclerosis
Atherosclerosis is a complex process to which many different factors contribute. Injury of the endothelium, proliferation of VSMCs, migration of monocytes/macrophages, and the regulatory network of growth factors and cytokines are important in the development of atherosclerosis. In addition, chronic inflammation of the vascular wall is also involved. As mentioned earlier, PPARγ has antiinflammatory effect. PPARγ ligands have been shown to reduce production of inflammatory cytokines, such as IL-1β, IL-6, inducible nitric oxide synthase and tumor necrosis factor-α (TNF-α), by inhibiting the activity of transcription factors such as activator protein-1 (AP-1), signal transducers and activators of transcription (STAT), and NF-κB in monocytes/macrophages. 2, 3 Those findings suggest that PPARγ activation may have beneficial effects in modulating inflammatory responses in atherosclerosis. Interestingly, expression of PPARγ has been demonstrated in atherosclerotic plaques. 8 Macrophages affect the vulnerability of plaque to rupture and they are implicated in the secretion of matrix metalloproteinases (MMPs), enzymes that are important in the degradation of extracellular matrix. In macrophages and VSMCs, PPARγ Circulation Journal Vol. 73, February 2009 ligands have been shown to reduce the expression of MMP-9, resulting in the inhibition of migration of VSMCs, and plaque destabilization. 3, 4 Although activation of T lymphocytes represents a critical step in atherosclerosis, PPARγ ligands also reduce the activation T lymphocytes. 18 Recently, it was reported that PPARγ is a key regulator of M1/M2 polarization. 19 Classically activated macrophages (M1) express a high level of pro-inflammatory cytokines and reactive oxygen species, whereas alternatively activated macrophages (M2) play an antiinflammatory role in atherosclerosis. PPARγ agonists prime monocytes into M2 and PPARγ expression is enhanced by M2 differentiation. 20 VSMC proliferation and migration are also critical events in atherosclerosis and vascular-intervention-induced restenosis. TZDs inhibit both these changes in the VSMCs and neointimal thickening after vascular injury. [21] [22] [23] [24] Furthermore, TZDs induce apoptosis of VSMCs via p53 and Gadd45. 25, 26 Angiotensin II (AngII) plays an important role in vascular remodeling via the AngII type 1 receptor (AT1R) and accelerates atherosclerosis. Although AngII induces transcriptional suppression of PPARγ, activation of PPARγ inhibits AT1R gene expression at a transcriptional level in VSMCs. [27] [28] [29] Expression of adhesion molecule by ECs, leading to adhesion of leukocytes, is a critical early step in atherosclerosis. PPARγ ligands inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 and decreased production of chemokines, such as IL-8 and monocyte chemotactic protein-1 (MCP-1) via suppressions of AP-1 and NF-κB activities in ECs. [30] [31] [32] PPARγ ligands also inhibit MCP-1-induced monocytes migration. 33 Endothelin-1 (ET-1) is involved in the regulation of vascular tone and endothelial functions, and induces proliferation of VSMCs. In bovine aortic ECs, PPARγ ligands suppressed transcription of the ET-1 promoter by interfering with AP-1. 34 PPARγ activation by major oxidized lipid components of ox-LDL, 9-HODE and 13-HODE has an important role in the development of lipid-accumulating macrophages through transcriptional induction of CD36, a scavenger receptor. 35 These findings suggest that atherogenic ox-LDL particles could induce their own uptake through activation of PPARγ and expression of CD36, leading to atherosclerosis. However, several studies have demonstrated that activation of PPARγ does not promote lipid accumulation in either mouse or human macrophages. [36] [37] [38] Liver X receptor α (LXRα) is an oxysterol receptor that promotes cholesterol excretion and efflux by modulating expression of ATP-binding cassette transporter 1 (ABCA1). 37, 38 LXRα was recently identified as a direct target of PPARγ in mouse and human macrophages. 39, 40 Although the PPARγ-induced increase in CD36 expression might accelerate lipid uptake in macrophages, subsequent activation of LXRα and upregulation of ABCA1 appear to induce lipid efflux.
Diep et al have demonstrated that rosiglitazone and pioglitazone attenuate the development of hypertension and structural abnormalities, and improve endothelial dysfunction in AngII-infused rats. 41 These TZDs also prevented upregulation of AT1R, cell cycle proteins, and inflammatory mediators. Rosiglitazone, but not the PPARα ligand fenofibrate, prevented hypertension and endothelial dysfunction in DOCA-salt hypertensive rats. 42 It has been reported that serum levels of the soluble CD40 ligand are elevated in acute coronary syndrome and associated with increased cardiovascular risk. Treatment with rosiglitazone decreased the serum levels of soluble CD40 and MMP-9 in type 2 diabetic patients with coronary artery disease. 43 Taking all the evidence together, PPARγ ligands may prevent the progression of atherosclerotic lesions, particularly in patients with DM (Fig 2) .
PPARγ and Ischemic Heart Disease
As the effects of PPARγ on the heart are not fully understood, we and others have examined whether PPARγ is involved in various heart diseases. Although the expression of PPARγ in cardiac myocytes is low compared with adipocytes, PPARγ ligands seem to act on cardiac myocytes. 7, 44 We demonstrated that PPARγ ligands inhibited the cardiac expression of TNF-α at the transcriptional level, in part by antagonizing NF-κB activity. 7 Because TNF-α expression is elevated in the failing heart and has a negative inotropic effect on cardiac myocytes, treatment with PPARγ ligands may prevent the development of congestive heart failure. Diabetic cardiomyopathy, which is characterized by systolic and diastolic dysfunction, is a major complication of DM, and therefore TZDs seem to be beneficial for the impaired cardiac function in patients with DM. Following our study, the role of PPARγ in myocardial ischemia -reperfusion (IR) injury has been elucidated. [45] [46] [47] [48] In animal models, PPARγ ligands reduced the size of the myocardial infarct and improved contractile dysfunction after IR through inhibition of the inflammatory response. IR injury activates JNK, and subsequently JNK induces increases in both AP-1 DNA-binding activity and apoptotic cells. It has been shown in rats that rosiglitazone inhibits the activation of JNK and AP-1 after myocardial IR. 46 Furthermore, pioglitazone has been reported to attenuate left ventricular remodeling and heart failure after myocardial infarction (MI) in mice. 49 Both of these effects of TZDs ligands were associated with decreases in inflammatory cytokines and chemokines. 49, 50 
PPARγ and Cardiac Hypertrophy
The PPARγ ligands, troglitazone, pioglitazone and rosiglitazone, inhibited AngII-induced hypertrophy of neonatal rat cardiac myocytes. [51] [52] [53] Because generalized PPARγ gene deletion causes embryonic lethality, we examined the role of PPARγ in the development of cardiac hypertrophy in vivo using heterozygous PPARγ-deficient (PPARγ +/-) mice. 53 Pressure overload-induced cardiac hypertrophy was more prominent in heterozygous PPARγ +/-mice than in wild-type (WT) mice. Treatment with pioglitazone strongly inhibited the pressure overload-induced cardiac hypertrophy in WT mice and moderately in PPARγ +/-mice. 53 Thereafter, 2 other groups examined the role of PPARγ in the heart by using cardiomyocyte-specific PPARγ knockout mice. 54, 55 Duan et al reported that these mice develop cardiac hypertrophy through elevated NF-κB activity, 54 and unexpectedly, rosiglitazone induced cardiac hypertrophy in both the WT mice and cardiomyocyte-specific PPARγ knockout mice through activation of p38 MAP kinase independent of PPARγ. Ding et al reported that cardiomyocyte-specific PPARγ knockout mice displayed cardiac hypertrophy from approximately 3 months of age and then progress to dilated cardiomyopathy; 55 most mice died from heart failure within 1 year after birth. Mitochondrial oxidative damage and reduced expression of manganese superoxide dismutase were recognized in the cardiomyocyte-specific PPARγ knockout mice. 55 These mice models demonstrate that PPARγ is essential for protecting cardiomyocytes from stress and oxidative damage, although the expression level of PPARγ in cardiomyocytes is low. On the other hand, Son et al demonstrated that cardiomyocyte-specific PPARγ transgenic mice develop dilated cardiomyopathy associated with increased uptake of both fatty acid and glucose. 56 Rosiglitazone increased this glucolipotoxicity in cardiomyocytespecific PPARγ transgenic mice. If PPARγ in the heart is expressed at a high level, rosiglitazone may cause cardiotoxic effects; however, as noted earlier the expression level of PPARγ in the heart is quite low.
PPARγ and Myocarditis
Experimental autoimmune myocarditis (EAM) is a Tcell-mediated disease characterized by infiltration of T cells and macrophages, leading to massive myocarditis necrosis, which develops into heart failure in the chronic phase. 57 The onset of EAM in rats occurs approximately 2 weeks after the first immunization with porcine cardiac myosin. At this time, small numbers of CD4 + T cells and macrophages start to infiltrate into the myocardium and various cytokines are expressed. Macrophage inflammatory protein-1α (MIP-1α) is a C-C chemokine that induces leukocyte accumulation in tissue sites of inflammation. We previously demonstrated that MIP-1α mRNA and protein are highly expressed in the hearts of rats with EAM from day 11 after first immunization. 57 Th1 cells produce interferon-γ (IFN-γ), which is mainly involved in cell-mediated immune responses, whereas Th2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13, which participate in humoral responses. Immune dysfunction associated with autoimmune disease is known to involve an imbalance between Th1 and Th2 cells.
It has been reported that pioglitazone treatment markedly reduces the severity of myocarditis in a rat model of EAM. 58, 59 Pioglitazone suppressed expression of inflammatory cytokines and activation of myocardiogenic T cells in the myocardium of EAM rats. 58 The mRNA levels of MIP-1γ were upregulated in the hearts of EAM rats, but not in the hearts of those in the pioglitazone group. Furthermore, treatment with pioglitazone decreased the expression levels of pro-inflamatory cytokine (TNF-α and IL-1β) genes and Th1 cytokine (IFN-γ) genes, and increased the expression levels of Th2 cytokine (IL-4) gene. 59 These results suggest that PPARγ ligands may have beneficial effects on myocarditis by inhibiting MIP-1α expression and modulating the Th1/Th2 balance (Fig 3) . Actions of PPARγ in heart diseases. PPARγ inhibits the progression of heart failure following cardiac hypertrophy, myocardial infarction, ischemia -reperfusion injury, and myocarditis. PPAR, peroxisome proliferatoractivated receptor.
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Efficacy and Safety of TZD Treatment in the Clinical Setting
Despite the beneficial effects of TZDs in the basic experiments, their propensity to cause fluid retention is a serious side-effect. Clinical studies report TZD-induced peripheral fluid retention, and an increase in plasma volume in 2-5% of patients on monotherapy. 60 Fluid retention was more likely to occur with concomitant insulin use, and in patients with underlying cardiac dysfunction or renal insufficiency. The exact mechanisms for TZD-induced fluid retention are not well understood, and it remains unclear whether TZDs directly cause the development of de novo congestive heart failure. It is known that the level of vascular endothelial growth factor is increased in the patients who develop fluid retention with TZD therapy 61 and this may lead to peripheral edema through increased vascular permeability. The insulin-sensitizing action of TZDs also induces water and salt retention. PPARγ is highly expressed in the kidney and collecting-duct-specific PPARγ knockout mice demonstrated no effects of TZD on fluid retention or the expression level of sodium channel ENaC-γ. 62, 63 These findings suggest that activation of the sodium channel in the collecting duct cells expressing PPARγ may be a mechanism of fluid retention. In patients without evidence of heart failure, careful examination did not reveal any worsening of left ventricular function by TZDs. 64 There are very few studies investigating the safety of TZDs in patients with preexisting heart failure. Although a recent study demonstrated that there is not a direct association between the risk of fluid retention and the baseline degree of severity of heart failure in diabetic patients treated with TZDs, the prescription of TZDs for patients with established heart failure should be avoided at present. 60, 65 The PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events) study has shown that pioglitazone significantly decreases the occurrence of all-cause mortality, nonfatal MI, and nonfatal stroke in patients with type 2 DM and macrovascular diseases. 66 Pioglitazone significantly reduced the occurrence of fatal and nonfatal MI by 28% in the PROactive study. 66 Although there was a 1.6% absolute increase in heart failure hospitalizations in the pioglitazone group compared with the placebo group, the number of heart-failure-related deaths was almost identical. In contrast to the PROactive study, it has been recently reported that rosiglitazone treatment is associated with increased incidence of MI by meta-analysis. 67, 68 Although meta-analysis has a number of limitations and the increased risk in MI is still controversial, those results attracted the attention of many clinicians. There are some differences in the actions of pioglitazone and rosiglitazone. Pioglitazone has more beneficial effects on the lipid profile than rosiglitazone. 69 As mentioned earlier, rosiglitazone, but not pioglitazone, induced cardiac hypertrophy by a non-PPARγ-mediated pathway. 54 Pioglitazone represses NF-κB activation and VCAM-1 expression in a PPARα-dependent manner. 70 Pioglitazone was recently reported to increase the number and function of endothelial progenitor cells (EPCs) in patients with stable coronary artery disease and normal glucose tolerance. 71 Pioglitazone may induce angiogenesis by modulating EPC mobilization and function. In the future, more mechanistic studies are required to investigate the differences in action between pioglitazone and rosiglitazone.
Conclusions
The American Heart Association (AHA) and American Diabetes Association (ADA) have released a consensus statement that advises caution regarding the use of TZDs in patients with known or suspected heart failure. 72 Because there is a possibility that TZDs may unmask asymptomatic cardiac dysfunction by increasing plasma volume, they should be avoided in patients with congestive heart failure of New York Heart Association (NYHA) class III or IV. The data from in vitro studies suggest that TZDs exert direct actions on vascular cells and cardiomyocytes, independent of their glucose-mediated mechanisms. Further studies using tissue-specific gene targeting mice are necessary to address in vivo the pleiotropic effects of PPARγ on the cardiovascular system. If the beneficial roles of PPARγ can be solved, modulation of PPARγ may become a promising therapeutic strategy for cardiovascular diseases. Because cardiac hypertrophy can be seen even in normotensive diabetic patients, and diabetic cardiomyopathy is a major complication of DM, antidiabetic agents such as the TZDs would be expected to have beneficial effects on cardiac hypertrophy and dysfunction in patients with DM. It has been already clarified that 3-hydroxy-3-methyglutaryl-coenzyme A reductase inhibitors, statins, have pleiotropic effects in cardiovascular diseases. The effects of PPARγ ligands are similar to those of statins in many respects. A recent study demonstrated that statins activate PPARγ through ERK and p38 MAP-kinase-dependent cyclooxygenase-2 expression in macrophages. 73 Further studies are needed to elucidate the molecular mechanisms of the pleiotropic effects of PPARγ ligands in cardiovascular disease.
